Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
Compare our trio of powerful circulating tumor cell (CTC) tests. These innovative tools leverage liquid biopsies, a simple blood test, to provide vital information about your unique cancer.
Unlike traditional biopsies that require tissue extraction, these tests offer a minimally invasive approach to gain valuable insights into your cancer's characteristics. Learn how the information returned by each test can empower you and your practitioner to make informed decisions about your treatment plan and prognosis.
The comparison below gives you an at-a-glance look at what each test focuses on, from comprehensive profiling and establishing a baseline for specific cancers to monitoring treatment response.
Provides a comprehensive picture of your cancer, including CTC count, markers associated with different cancer types (phenotype), and potential for recurrence (stemness markers).
It is ideal for understanding overall cancer progression and prognosis.
If you have a confirmed diagnosis of a specific cancer type, Oncotrail RGCC can establish a baseline of your cancer status at the beginning of treatment.
It focuses on markers relevant to your particular cancer.
This test simply checks for the presence and concentration of CTCs in your blood.
It's useful for monitoring treatment effectiveness and can be part of an interim analysis strategy.
7-10 days after sample is received
7-10 days after sample is received
7-10 days after sample is received
10-15 ml peripheral whole blood
Flow Cytometry
Flow Cytometry
Flow Cytometry
Applicable for all cancer types (except brain and CNS cancers, which require a tissue or CSF sample instead of blood sample)
(Specific for Breast, Colon, GI, Lung, Melanoma, Prostate, and Sarcoma)
Provides a comprehensive picture of your cancer, including CTC count, markers associated with different cancer types (phenotype), and potential for recurrence (stemness markers).
It is ideal for understanding overall cancer progression and prognosis.
If you have a confirmed diagnosis of a specific cancer type, Oncotrail can establish a baseline of your cancer status at the beginning of treatment.
It focuses on markers relevant to your particular cancer.
This test simply checks for the presence and concentration of CTCs in your blood.
It's useful for monitoring treatment effectiveness and can be part of an interim analysis strategy.
7-10 days after sample is received
7-10 days after sample is received
7-10 days after sample is received
7–10 ml peripheral whole blood
7–10 ml peripheral whole blood
7–10 ml peripheral whole blood
Flow Cytometry
Flow Cytometry
Flow Cytometry
All types of cancers
All types of cancers
All types of cancers
Unlike the CTC tests that focus on circulating tumor cells, our Onconomics panel of tests delves deeper into the genetic and physiological makeup of your cancer, alongside its response to various treatment options. This set of tests is a powerful tool designed to empower personalized cancer treatment plans.
The Onconomics panel of tests analyze your cancer cells on a molecular level and provide actionable insights for:
Leverage the power of our Onconomics panels to collaborate with your doctor on a treatment strategy precisely tailored to your unique cancer.
Our most comprehensive treatment testing tool that provides information to help build cancer treatment protocols for patients.
It is a combination of the Onconomics and the Onconomic Extracts tests.
A subset of the Onconomics Plus panel. Can be used to assess the effectiveness of specific cancer drugs and targeted therapies.
Also informs on the gene expression of your cancer cells.
Provides highly detailed information about how effective specific natural substances and plant extracts are, against your cancer.
Also informs on the gene expression of your cancer cells.
A subset of the Onconomics Extracts+ panel. Answers the question, “Which natural substances are most effective for targeting your cancer?”
Flow Cytometry (FACS)
Molecular biology-based assays (qPCR-microArrays)
Cell Cultures (3D)
Flow Cytometry (FACS)
Molecular biology-based assays (qPCR-microArrays)
Cell Cultures (3D)
Flow Cytometry (FACS)
Molecular biology-based assays (qPCR-microArrays)
Cell Cultures (3D)
Flow Cytometry (FACS)
Molecular biology-based assays (qPCR-microArrays)
Cell Cultures (3D)
Blood sample.
A tissue sample is required for tumors of the central nervous system.
Blood sample.
A tissue sample is required for tumors of the central nervous system.
Blood sample.
A tissue sample is required for tumors of the central nervous system.
Blood sample.
A tissue sample is required for tumors of the central nervous system.
15-25 ml peripheral whole blood.
Tissue sample qty: Minimum 400mg.
15-25 ml peripheral whole blood.
Tissue sample qty: Minimum 400mg.
15-25 ml peripheral whole blood.
Tissue sample qty: Minimum 400mg.
15-25 ml peripheral whole blood.
Tissue sample qty: Minimum 400mg.
7-10 days after sample is received
7-10 days after sample is received
7-10 days after sample is received
7-10 days after sample is received
Our most comprehensive treatment testing tool that provides information to help build cancer treatment protocols for patients.
It is a combination of the Onconomics and the Onconomic Extracts tests.
A subset of the Onconomics Plus panel. Can be used to assess the effectiveness of specific cancer drugs and targeted therapies.
Also informs on the gene expression of your cancer cells.
Provides highly detailed information about how effective specific natural substances and plant extracts are, against your cancer.
Also informs on the gene expression of your cancer cells.
A subset of the Onconomics Extracts+ panel. Answers the question, “Which natural substances are most effective for targeting your cancer?”
All types of Cancers
All types of Cancers
All types of Cancers
All types of Cancers
Flow Cytometry (FACS)
Molecular biology-based assays (qPCR-microArrays)
Cell Cultures (3D)
Flow Cytometry (FACS)
Molecular biology-based assays (qPCR-microArrays)
Cell Cultures (3D)
Flow Cytometry (FACS)
Molecular biology-based assays (qPCR-microArrays)
Cell Cultures (3D)
Flow Cytometry (FACS)
Molecular biology-based assays (qPCR-microArrays)
Cell Cultures (3D)
Blood sample.
A tissue sample is required for tumors of the central nervous system.
Blood sample.
A tissue sample is required for tumors of the central nervous system.
Blood sample.
A tissue sample is required for tumors of the central nervous system.
Blood sample.
A tissue sample is required for tumors of the central nervous system.
15–25 ml peripheral whole blood.
Qty: Minimum 400mg
15–25 ml peripheral whole blood.
Qty: Minimum 400mg.
15-25 ml peripheral whole blood.
Tissue sample qty: Minimum 400mg.
15–25 ml peripheral whole blood.
Qty: Minimum 400mg.
7-10 days after sample is received
7-10 days after sample is received
7-10 days after sample is received
7-10 days after sample is received
Start your journey to empowering information for your cancer treatment today by contacting us online.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s Oncocount and Oncotrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s OncoCount and OncoTrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Read more about our therapies on our website: https://rgcc-international.com/rgcc-therapies/
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient’s genes.
Individualized treatment for cancer is the focus behind RGCC’s testing protocols and advanced therapy options. Our slate of tests analyzes the state of a person’s cancer by looking at the cellular and genetic makeup of each patient. Our test results give you information that acts as a blueprint for what treatment protocols are likely to show the most efficacy for your specific biology.
Learn more about RGCC at
https://rgcc-international.com/
Follow us on social media to find out the latest news and updates from our experts.
Facebook: https://www.facebook.com/profile.php?id=61554630098937
Instagram: https://www.instagram.com/rgcc_north_america/
LinkedIn: https://www.linkedin.com/company/r-g-c-c-international-gmbh/
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
Applicable for all cancer types (except brain and CNS cancers, which require a tissue or CSF sample instead of blood sample)